Designing of Multi-Epitope Peptide Vaccine Based on Outer Membrane Proteins OmpF, OmpC, and PgtE of Salmonella enterica Typhi

Document Type : Original Articles

Authors

1 Department of Biology, Faculty of Science, University of Jiroft, Jiroft, Iran

2 Department of Animal Science, Faculty of Agriculture, University of Jiroft. Jiroft, Iran.

3 Department of Chemistry, Faculty of Science, University of Jiroft, Jiroft, Iran

10.32592/ARI.2023.78.5.1440

Abstract

Consumption of contaminated water and foods by Salmonella Typhi cause the most common enteric disease known as Typhoid fever in both humans and animals. Despite the existence of various vaccines but infectious diseases remain a major cause of mortality worldwide. Nowadays, in-silico tools design a reliable and stable vaccine to combat such infections. The study aimed to design and evaluate a multi-epitope vaccine based on the outer-membrane proteins of Salmonella Typhi. B-cells and T-cells epitopes were predicted. Predicted epitopes were connected by AAY, KK, and GPGPG linkers. Heparin-Binding Hemagglutinin Adhesin (HBHA) has been attached to the N-terminal of the final vaccine as a potent immune adjuvant. Epitope’s antigenicity, allergenicity, immunogenicity, and physicochemical characteristics were defined using in-silico tools. Molecular docking of vaccine-TLR4 was done. ∆G of vaccine-TLR4 is -3.91×104 Kcal mol-1 with 1.93 RMSD. The results indicated protein was stable and non-allergen. In conclusion, the multi-epitope vaccine base on outer membrane proteins of the Salmonella Typhi bacterium might be considered to combat typhoid fever.

Keywords

Main Subjects


1. Introduction

Salmonella enterica is a gram-negative bacterium that causes salmonellosis and belongs to the Enterobacteriaceae family. S. enterica is a flagellating bacillus that causes gastrointestinal disease in humans and animals ( 1 ). There are six subspecies of S. enterica, which are: Enterica, Arizonae, Diarizonae, Salamae, Indica, and Houtenae ( 2 - 4 ). There are over 2600 Salmonella enterica serovars, and the most important serovars of S. enterica are Salmonella Typhi and Salmonella Typhimurium ( 5 ). Salmonella Typhi causes typhoid fever with typical symptoms, such as persistent fever, chills, and abdominal pain, killing many people each year. Salmonella is transmitted through feces and spread through contaminated water and food ( 6 ). An estimated 11 to 21 million cases of typhoid fever and approximately 128000 to 161000 deaths worldwide each year ( 7 ). Antimicrobial resistance of pathogenic intestinal bacteria is one of the global health problems today. Multiresistance of S. Typhi to ampicillin, chloramphenicol, and cotrimoxazole has been reported ( 8 - 10 ).

In recent years, various approaches have been taken to develop vaccines against Salmonella Typhi. This vaccine contains injectable Ty21a and Vi, which are moderately effective (50-80% protection) ( 11 ). Despite the fact that vaccines against typhoid fever are commonly administered, it is important to consider the immune mechanisms for enteric infections ( 12 ).

In recent years, immunoinformatics has been well established and applied to vaccine information of various microorganisms ( 13 ). Data based on the genomes of microorganisms can help predict the epitopes that can interact with the host immune system. However, mapping epitopes in immunogenic proteins is critical for peptide vaccine development. In S. Typhi, the immune potential of outer membrane proteins (Omps) has been studied ( 14 ). They are good candidates for the development of multi-epitope vaccines against Salmonella Typhi. The studies revealed that the epitopes can bind to human leukocyte antigen alleles (HLA) and major histocompatibility complex (MHC) class I and class II proteins, which play a central role in the immune system and are recognized by cytotoxic CD8+ T-cells and CD4+ T-cells, respectively ( 15 ). CD4+ and CD8+ epitopes are used for vaccine models that target a variety of pathogens ( 16 ). Vaccines based on multiple epitopes are cheaper, safe, time-saving, stable, highly specific, and bind to multi-epitope alleles simultaneously compared with vaccines produced in a conventional manner ( 17 ). Therefore, the goal was to develop an effective multiepitope vaccine against the bacterium S. Typhi. The vaccine was developed from the antigens OmpC, OmpF, and PgtE. Finally the docking of the ligand to a receptor (TLR4) was analyzed. Stability energy and electron surface map analysis was performed for a refined vaccine with TLR4 receptor.

2. Methods and Materials

2.1. Finding the protein retrieval

The sequence of OmpF (Uni-prot Accession no Q56113), OmpC (Uni-prot Accession no P0A264), and PgtE (Uni-prot Accession no P06185) from S. Typhi was retrieved from http://www.uniprot.org. The sequence obtained was stored in a text-based format known as FASTA.

2.2. Prediction of sequence-based CD8+ epitopes

The IEDB Analysis Resource tool was used to predict MHC-I alleles (http://tools.iedb.org/mhci), and a threshold of 0.5 was used to identify nine mer-amino acids. This software is freely available on the public website. This web server predicts epitopes in proteins based on accessibility, flexibility, antigenicity, and hydrophobicity.

2.3. Prediction of sequence-based CD4+ epitopes

IEDB (http://tools.iedb.org/mhcii/) was used to predict nine mer-linear CD4+ alleles. For this tool, the criterion for selecting candidate epitopes is a p-value greater than 0.5.

2.4. B-cell epitope

B-cells are lymphocytes responsible for humoral immunity and produce antibodies. IEDB software was used to predict and select appropriate linear and continuous B-cell epitopes in the vaccine structure. This web-based software allows prediction and analysis of B-cell epitopes using computational tools.

2.5. Allergenicity, Antigenicity, and immunogenicity

The VaxiJen server (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html) was used to predict the antigenic properties of epitopes. This server determines the antigenicity of the sequence based on the physicochemical properties of the proteins with a cut-off value of 0.5 and independent of the orientation of the protective antigens.

We used the AllerTop server (http://www.ddg-pharmfac.net/AllerTOP) to test the allergenicity of epitopes. The immunogenicity of OmpF, OmpC, and PgtE epitopes was checked at http://tools.iedb.org/immunogenicity. This web server predicts vaccine allergenicity based on key physical and chemical properties of the proteins.

2.6. Physicochemical activities

The ProtParam server (http://web.expasy.org/protparam) is used to study the physicochemical activities. It is used to report the amino acid composition, theoretical pI, molecular weight (MW), instability index, half-life, aliphatic index, and grand average hydropathy (GRAVY) of the construct.

2.7. Design and fusion of Epitopes

Epitopes were arranged as CD4+, CD8+, and B-cell of OmpF, OmpC, and PgtE, respectively (Fig. 1). Linker sequences of AAY were used in the case of MHC- I, KK for MHC- II, and GPGPG were incorporated into B-cell epitopes. Immunogenic proteins can increase the potency and efficacy of an epitope-based vaccine. For example, HBHA (AN: ZP_07011362.1) from Mycobacterium tuberculosis (N-terminal of the vaccine) was used as an adjuvant that can bind to TLR4 ( 18 ). The EAAAK linker with helical structure was placed on both sides of HBHA to minimize domain interaction ( 19 ).

Figure 1. Designing and fusing of epitopes

2.8. Prediction of secondary structure

PSIPRED tool (http://bioinf.cs.ucl.ac.uk/psipred) was used to predict the secondary structure. Four conformational states (helices, sheets, turns, and coils) of candidate genes were analyzed.

2.9. Modeling and refinement of the tertiary structure

RAPTORX server (http://raptorx.uchicago.edu/StructPredV2/) was used to predict the 3D structure. PyMOL is a comprehensive molecular software used to visualize 3D designs. ProSA is a powerful server (http://prosa.services.came.sbg.ac.at/prosa.php) used to check for possible errors. The predicted 3D structural model was refined using the Galaxyrefine server (https://galaxy.seoklab.org/cgi-bin/submit.cgi?type=REFINE). Ramachandran plot (http://swissmodel.expasy.org/workspace) predicts the structural stereochemical property in PROCHECK software ( 20 ).

2.10. Docking of vaccine (ligand) to TLR4 (receptor)

Ligand-receptor docking is an in-silico method (ClusPro) used to determine the best match and estimate the binding dependence between ligand and receptor. For docking, water molecules and additional binding molecules of the ligand (unsuitable epitopes) were separated from the receptor, polar hydrogen bonds were added to the receptor, and finally the energy of the system was optimized.

2.11. Energy and surface map of a vaccine-TLR4 complex

To confirm the stability of the model structure, the ligand-TLR4 construct and the surface map of the vaccine, a computational analysis was performed using Amber10: EHT/all-atom force field with rigid water molecules at room temperature.

3. Results

In the current study, a total of 18 epitopes with nine mer lengths were obtained from three genes and subjected to vaccine modeling. The immunogenicity score of all MHC- I was retrieved from the IEDB server. The results showed that the range of immunogenicity score of MHC-I epitopes was between -0.008 and -0.2 (Table. 1). To see the MHC-II epitopes, the IEDB tools were used and 9 epitopes of 15 mer length were found. To detect linear B-cell epitopes, the sequences were subjected to the IEDB antigen sequence properties, and 22 epitopes from 9 to 34 mer in length were obtained (Table. 2).

MHC- I
Gene Alleles Start End Sequence (peptide) Score
OmpF H2-Db 17 25 AATANAAEI 0.834497
H2-Dd 195 203 VGYTMAYEF 0.116599
H2-Kb 320 328 ATYYFNKNM 0.791775
H2-Kd 239 247 KYDANNVYL 0.779589
H2-Kk 260 268 VENTVTDTV 0.856953
H2-Ld 132 140 APYFSGETW 0.340812
OmpC H2-Db 150 158 ATYRNTDFF 0.794161
H2-Dd 272 280 SNPSTSYGF 0.184829
H2-Kb 334 342 ATYYFNKNM 0.791775
H2-Kd 245 253 KYDANNIYL 0.740712
H2-Kk 179 187 GENTNGRSL 0.681186
H2-Ld 370 378 VALGLVYQF 0.236613
PgtE H2-DB 168 176 YIYDNGRYI 0.504859
H2-Dd 184 192 RGIGYSQRF 0.153985
H2-Kb 257 265 SNAKIFAEF 0.550266
H2-Kd 253 261 YYITSNAKI 0.949666
H2-Kk 271 279 EEGKGGTQI 0.882369
H2-Ld 30 38 SPDSVTTSL 0.74587
MHC- II
Gene Alleles Start End Sequence Percentile
OmpF H2-IAd 1 15 MMKRKILAAVIPALL 1.03
H2-IAb 11 25 IPALLAAATANAAEI 0.09
H2-IEd 76 90 FGQWEYRTKADRAEG 2.30
OmpC H2-IAd 8 22 LLVPALLVAGAANAA 11.00
H2-IAb 11 25 PALLVAGAANAAEIY 0.69
H2-IEd 332 346 VGATYYFNKNMSTYV 10.15
PgtE H2-IAd 1 15 MKKHAIAVMMIAVFS 2.85
H2-IAb 248 262 IDAGYYITSNAKIFA 4.10
H2-IEd 225 239 DEHYMRKLTFREKTE 2.77
Table 1.MHC- I (CD8+ T-cell) and MHC- II (helper T lymphocyte or CD4+)
Gene Start End Sequence (peptide) Length
OmpF 44 57 VWTTTGDSKNADQT 14
85 97 ADRAEGEQQNSNL 13
135 153 FSGETWGGAYTDNYMTSRA 19
176 194 QYQGKNQDNHSINSQNGDG 19
215 232 SKRTNDQQDRDGNGDRAE 18
254 276 TRNMSIVENTVTDTVEMANKTQN 23
298 312 SKGKQLNGADGSADL 15
337 352 NLLDENDYSSSYVGTD 16
OmpC 42 55 HYFSDDKGSDGDQT 14
81 92 IQGNQTEGSNDS 12
128 147 LPEFGGDTYGADNFMQQRGN 20
169 193 QYQGKNGSVSGENTNGRSLLNQNGD 25
215 237 TSKRTADQNNTANARLYGNGDRA 23
260 284 TYNATRFGTSNGSNPSTSYGFANKA 25
309 326 KGKDISNGYGASYGDQDI 18
350 367 INLLDKNDFTRDAGINTD 18
PgtE 24 32 LFIPDVSPD 9
50 59 LVYDTDTGRK 10
94 127 SLASGSGHMVDHDWMSSEQPGWTDRSIHPDTSVN 34
167 181 SYIYDNGRYIGNFPH 15
233 241 LTFREKTEN 9
269 292 KYEEGKGGTQIIDKTSGDTAYFGG 24
Table 2.B-cell

The results showed (Table. 3) a total of nine interferon-γ- inducing epitopes (15 mer). A total of five interferon-γ- inducing epitopes were predicted with positive scores and four interferon-γ- generating epitopes were predicted with negative scores

Gene Start End Sequence IFN-γ Score
OmpF 1 15 MMKRKILAAVIPALL Positive 0.37242047
11 25 IPALLAAATANAAEI Positive 0.062773151
76 90 FGQWEYRTKADRAEG Positive 0.21147028
OmpC 8 22 LLVPALLVAGAANAA Positive 0.15535542
11 25 PALLVAGAANAAEIY NEGATIVE -0.042811389
332 346 VGATYYFNKNMSTYV NEGATIVE -0.56728272
PgtE 1 15 MKKHAIAVMMIAVFS Positive 0.66910732
248 262 IDAGYYITSNAKIFA NEGATIVE -0.22423073
225 239 DEHYMRKLTFREKTE NEGATIVE -0.32178762
Table 3.γ- Interferon

Antigenicity of the construct was indicated by ANTIGENpro for both CD4+ and CD8+ epitopes (Tables. 4 and 5).

Gene Sequence (peptide) Immunogenicity Score Antigenicity Score Probable Allergenicity
OmpF AATANAAEI 0.18032 0.8979 ANTIGEN PROBABLE ALLERGEN
VGYTMAYEF 0.13127 1.0554 ANTIGEN PROBABLE NON-ALLERGEN
ATYYFNKNM -0.08159 0.1067 NON-ANTIGEN PROBABLE NON-ALLERGEN
KYDANNVYL 0.07316 0.5367 ANTIGEN PROBABLE ALLERGEN
VENTVTDTV 0.13242 0.6525 ANTIGEN PROBABLE ALLERGEN
APYFSGETW 0.25568 0.1224 NON-ANTIGEN PROBABLE ALLERGEN
OmpC ATYRNTDFF 0.17454 -0.2619 NON-ANTIGEN PROBABLE ALLERGEN
SNPSTSYGF -0.30552 0.3842 NON-ANTIGEN PROBABLE NON-ALLERGEN
ATYYFNKNM -0.08159 0.1067 NON-ANTIGEN PROBABLE NON-ALLERGEN
KYDANNIYL 0.15064 0.6091 ANTIGEN PROBABLE NON-ALLERGEN
GENTNGRSL 0.10624 2.9062 ANTIGEN PROBABLE NON-ALLERGEN
VALGLVYQF -0.00144 0.8219 ANTIGEN PROBABLE NON-ALLERGEN
PgtE YIYDNGRYI 0.09454 -1.5659 NON-ANTIGEN PROBABLE NON-ALLERGEN
RGIGYSQRF -0.18915 0.0030 NON-ANTIGEN PROBABLE NON-ALLERGEN
SNAKIFAEF 0.11432 -0.1130 NON-ANTIGEN PROBABLE ALLERGEN
YYITSNAKI -0.01681 0.6889 ANTIGEN PROBABLE NON-ALLERGEN
EEGKGGTQI -0.10834 2.7029 ANTIGEN PROBABLE ALLERGEN
SPDSVTTSL -0.18663 0.9775 ANTIGEN PROBABLE ALLERGEN
Table 4.MHC- I antigenicity, allergenicity, and immunogenicity
Gene Sequence Antigenicity Score Probable Allergenicity
OmpF MMKRKILAAVIPALL 0.2413 NON-ANTIGEN PROBABLE NON-ALLERGEN
IPALLAAATANAAEI 0.5863 ANTIGEN PROBABLE NON-ALLERGEN
FGQWEYRTKADRAEG 0.9059 ANTIGEN PROBABLE NON-ALLERGEN
OmpC LLVPALLVAGAANAA 0.8210 ANTIGEN PROBABLE NON-ALLERGEN
PALLVAGAANAAEIY 0.5361 ANTIGEN PROBABLE ALLERGEN
VGATYYFNKNMSTYV 0.3450 NON-ANTIGEN PROBABLE NON-ALLERGEN
PgtE MKKHAIAVMMIAVFS 0.5106 ANTIGEN PROBABLE NON-ALLERGEN
IDAGYYITSNAKIFA -0.1221 NON-ANTIGEN PROBABLE NON-ALLERGEN
DEHYMRKLTFREKTE 0.4331 NON-ANTIGEN PROBABLE NON-ALLERGEN
Table 5.MHC- II antigenicity, allergenicity, and immunogenicity

The psipred server at http://bioinf.cs.ucl.ac.uk/psipred is used to display secondary structure. According to the results in Fig. 2 (a). Of the 749 amino acids analyzed, 246 (32.84%) were involved in α-helix formation, 94 (12.55%) in β- strand formation, and 410 (54.73%) were engaged in coil formation.

Figure 2. (a) Secondary structure, (b) Local model quality, (c) Z-score plot of refined model. The best model showed a Z-score of -5.38 (large black spot). Z-scores of all model protein chains (in PDB format) indicated by NMR spectroscopy (dark blue)

ProSAweb was used to predict the quality and errors of the 3D structure of the engineered vaccine. The Z-score of the best refined model was -5.38 (Fig.2 (b, c, and d)).

The Galaxy web server displayed the five models with GDT-HA, MolProbity, RMSD, and Ramachandran plot. Model 3 proved to be the best based on its parameters, including GDT-HA (0.939), MolProbity (2.111), and RMSD (0.468). The clash score of model 3 was 11.5 with a poor Rotamers score of 0.6 and a Rama favored score of 90.5. The Ramachandran diagram of the refined structure of the multi-epitope vaccine shows 39% helix, 9% beta and 51% coil of residues (Fig. 2 (e)).

ProtParam sever was used to check the physiochemical activities of the constructed model. The results showed that the isoelectric point (pI) of all vaccine is 5.00. The constructed vaccine consists of 749 amino acids with a molecular weight of 77981.61. The total number of residues with positive and negative charges was 93 and 72, respectively. The half-life of the vaccine is estimated to be one h in mammalian reticulocytes (in vitro), 30 min in yeast (in vivo), and > 10 h in E. Coli (in vivo). The hydrophobicity of the protein was estimated by a grand average of hydropathicity (GRAVY). GRAVY score of the construct was -0.821. The predicted scaled solubility was 0.582. The instability index of the protein was 16.19. In addition, the aliphatic index was 52.51.

Multi-epitope vaccine and TRL4 docking were performed using ClusPro server. Of the 10 models obtained, the model with the minimum energy value of -965.5 was considered. The best docking of a ligand-receptor is shown in Fig. 3.

Figure 3. Docked complex of ligand-receptor by the ClusPro server. (a): ligand with blue color and receptor (TLR4) with green color, (b): interacting amino acid residues of ligand and receptor, which are labeled in black. Results revealed a probable

To estimate the structural stability of the docked vaccine constructTLR4, some statistical features were analyzed based on the 100-ns trajectory of the molecular dynamics simulation and shown in Fig. 4 (a) and (b). The RMSD of all atoms in the ligand-receptor complex gradually increases with timeand persists until 20 ns. The RMSD curve of all atoms means that the ligand-receptor complex remained mostly stable, and the RMSD value converged within ~0 .1 nm. Moreover, the ∆G of the stable structure is -3.91×104 Kcal mol-1 with 1.93 RMSD. Van der Waals forces are a general term for the attraction of intermolecular forces between molecules. Fig. 5 (a) shows the Van der Waals surface of the vaccine construct-TLR4 complex. The Van der Waals forces depend on the distance between the atoms or molecules on the surface; the gray color shows that in this complex, the intermolecular forces are weak, resulting from the interactions between uncharged atoms/molecules. Fig. 5 (b) shows the electrostatic surface of the construct-TLR4 complex. The red site conducts the opposite electrostatic force, and the blue color shows the flattering posture of the molecule.

Figure 4. (a) Difference of ∆G of docking pose of vaccine with TRL4, and (b) RMSD structural stability analysis of vaccine with TRL4

Figure 5. Van der Waals, (a) and electrostatic (b) maps for a vaccine with TRL4

4. Discussion

Classical strategies are used for the development of most human vaccines ( 21 ). Because of its time-consuming and costly approach, reverse vaccinology, which includes genomic information, could predict antigenic proteins that elicit an immune response ( 22 ). Multi-epitope vaccines are planned for various bacteria and parasites ( 23 ). In the present study, the predicted epitopes were joined by different linkers (AAY, KK, and GPGPG) as cleavage sites. These linkers were used to increase protein stability ( 24 ). In the present study, the EAAAK linkers were used before and after the adjuvant. The EAAAK linkers are defined as rigid linkers that can separate and reduce the interaction between vaccine domains and increase the thermal stability of chimeric proteins ( 25 ). The dilysine linker (KK) has been used in multi-epitopes as a suitable linker for cathepsin B, enhancing T-cell antigen presentation and increasing immunogenicity ( 26 ). AAY linkers are efficiently cleaved in cells, reducing cross-linking, to improve multi-epitope vaccines ( 27 , 28 ). GPGPG linkers have been used for B-cell cross-linking ( 29 ). In addition, the GPGPG linker can elicit a helper T lymphocyte (HTL) response and abrogate the immunogenicity of the compound and restore immunogenicity ( 30 ).

The antigenic proteins of Salmonella Typhi were extracted from the NCBI protein database based on the FASTA format of their genes. Cytotoxic Tlymphocytes are CD8+ T-cell responses to cells with intracellular viral, bacterial, or protozoal infections. In the current study, lower percentile ranks were chosen because of the highest immunogenic properties of the epitopes (Table. 1). Epitopes identified by their corresponding receptors (B-cells) play an important role in vaccine modeling. Thus, 22 epitopes ranging from 9 to 34 mer in length were obtained. Antigenicity is the ability of an antigen to bind with specific antibodies and elicit an immunological response that includes allergenicity and immunogenicity. ANTIGENpro indicated a high probability of antigenicity for both CD4+ and CD8+ epitopes. Allergenic vaccines can induce sensitization and allergic reactions associated with the IgE antibody response, so the multi-epitope should be free of allergenicity.

The secondary structure of the construct showed the formation of α-helix, β-strands, and coil. In addition, the 3D structure of the vaccine was displayed using Raptrox and refined using GalaxyRefine server. The 3D structure of the engineered vaccine was within the range of native proteins with similar sizes. The Galaxy web server showed that model 3 was the best based on its parameters, including GDT-HA, MolProbity, and RMSD. The clash score of the best model showed a poor rotamer score.

In the current study, the isoelectric point of the vaccine indicates the basic behavior of the protein. ProtParam sever indicates the basic behavior of the protein with positive and negative charges. GRAVY score of the construct indicates that the molecule is hydrophilic. The instability index of the protein indicated a stable molecule.

The results showed that the RMSD of all atoms in the ligand-receptor complex increased with time. The RMSD diagram showed that the ligand-receptor complex remained mostly stable. Van der Waals forces are weak and arise from the interactions between uncharged atoms/molecules.

Conclusion: Salmonella Typhi causes typhoid fever and death of many people every year. The resistance of S. Typhi to many antibiotics, suggesting that it is extremely dangerous to living organisms. Since a polyepitope vaccine based on immunogenic outer membrane proteins of S. Typhi, was developed in the present study, the results of in-silico analyses indicate that the constructed vaccine can be used to control typhoid fever and needs further investigation.

Authors’ Contribution

Fereshteh Ezzati Ghadi: Supervision, Writing, Revision, Investigation,

Zahra Roudbari: Writing, Methodology, Revision,

Razieh Razavi: Writing, Methodology, Visualization

Ethics

Not applicable.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Hassan N, Randhawa CS, Narang D. Diagnostic Workup in Relation to Odds of Clinico-Fecal Predictors in Adult Dairy Cattle and Buffalo with Chronic Diarrhea. Iranian Journal of Veterinary Medicine. 2022; 16(4)
  2. Chand Y, Alam MA, Singh S. Pan-genomic analysis of the species Salmonella enterica: identification of core essential and putative essential genes. Gene Reports. 2020; 20:100669.
  3. Haghighatnezhad H, Peighambari SM, Razmyar J. Detection of Virulence Genes among Salmonella serovar Infantis Isolated from Poultry Sources. Iranian Journal of Veterinary Medicine. 2022; 2
  4. Peighambari SM, Yazdani A, Taheri H, Shahcheraghi F. Plasmid Profile and Enterobacterial Repetitive Intergenic Consensus-PCR Characterization of Salmonella Infantis Isolates Recovered From Poultry Sources. Iranian Journal of Veterinary Medicine. 2023; 17(1)
  5. Liu Y, Jiang J, Ed-Dra A, Li X, Peng X, Xia L, Guo Q, Yao G, Yue M. Prevalence and genomic investigation of Salmonella isolates recovered from animal food-chain in Xinjiang, China. Food Research International. 2021 Apr 1; 142:110198.
  6. Baliban SM, Lu Y-J, Malley R. Overview of the nontyphoidal and paratyphoidal Salmonella vaccine pipeline: current status and future prospects. Clin Infect Dis. 2020; 71(Supplement_2):S151-4.
  7. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-88.
  8. Mohsin S, Aziz Q, Muurlink O, Taylor-Robinson A. Burden of antibiotic resistance among children with typhoid in Gadap Town, Karachi, Pakistan. Microbes Infect Dis. 2022; 3(1):81-91.
  9. Gholipour-Shoshod A, Rahimi S, Salehi TZ, Torshizi MA, Behnamifar A, Ebrahimi T, Valizadeh M, Ganjpoor F. Evaluating the Competitiveness of Medicinal Plants With Antibiotics to Control Salmonella Enterica Serovar Typhimurium in Broiler Chickens. Iranian Journal of Veterinary Medicine. 2023; 17(2):155-66.
  10. Ali Anvar SA, Nowruzi B, Afshari G. A Review of the Application of Nanoparticles Biosynthesized by Microalgae and Cyanobacteria in Medical and Veterinary Sciences. Iranian Journal of Veterinary Medicine. 2023; 17(1)
  11. Guzman CA, Borsutzky S, Griot-Wenk M, Metcalfe IC, Pearman J, Collioud A, et al. Vaccines against typhoid fever. Vaccine. 2006; 24(18):3804-11.
  12. Syed KA, Saluja T, Cho H, Hsiao A, Shaikh H, Wartel TA, et al. Review on the recent advances on typhoid vaccine development and challenges ahead. Clin Infect Dis. 2020; 71(Supplement_2):S141-50.
  13. Arora N, Keshri AK, Kaur R, Rawat SS, Prasad A. Immunoinformatic Approaches for Vaccine Designing for Pathogens with Unclear Pathogenesis. In: Vaccine Design. Springer; 2022.
  14. Carreño JM, Perez-Shibayama C, Gil-Cruz C, Lopez-Macias C, Vernazza P, Ludewig B, et al. Evolution of Salmonella Typhi outer membrane protein-specific T and B cell responses in humans following oral Ty21a vaccination: A randomized clinical trial. PLoS One. 2017; 12(6):e0178669.
  15. Wieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg S, Noé F, et al. Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. Front Immunol. 2017; 8:292.
  16. Dar H, Zaheer T, Rehman MT, Ali A, Javed A, Khan GA, et al. Prediction of promiscuous T-cell epitopes in the Zika virus polyprotein: An in silico approach. Asian Pac J Trop Med. 2016; 9(9):844-50.
  17. Naz A, Shahid F, Butt TT, Awan FM, Ali A, Malik A. Designing multi-epitope vaccines to combat emerging coronavirus disease 2019 (COVID-19) by employing immuno-informatics approach. Front Immunol. 2020; 1663
  18. Jung ID, Jeong SK, Lee C-M, Noh KT, Heo DR, Shin YK, et al. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist. Cancer Res. 2011; 71(8):2858-70.
  19. Makitrynskyy R, Ostash B, Tsypik O, Rebets Y, Doud E, Meredith T, et al. Pleiotropic regulatory genes bldA, adpA and absB are implicated in production of phosphoglycolipid antibiotic moenomycin. Open Biol. 2013; 3(10):130121.
  20. Laskowski RA, Rullmann JAC, W MAM K R, Thornton JM. J Biomol NMR. 1996; 8:477-86.
  21. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021; 21(2):83-100.
  22. Aldakheel FM, Abrar A, Munir S, Aslam S, Allemailem KS, Khurshid M, et al. Proteome-Wide Mapping and Reverse Vaccinology Approaches to Design a Multi-Epitope Vaccine against Clostridium perfringens. Vaccines. 2021; 9(10):1079.
  23. Aslam S, Ashfaq UA, Zia T, Aslam N, Alrumaihi F, Shahid F, et al. Proteome based mapping and reverse vaccinology techniques to contrive multi-epitope based subunit vaccine (MEBSV) against Streptococcus pyogenes. Infect Genet Evol. 2022; 100:105259.
  24. Dey J, Mahapatra SR, Raj TK, Kaur T, Jain P, Tiwari A, et al. Designing a novel multi-epitope vaccine to evoke a robust immune response against pathogenic multidrug-resistant Enterococcus faecium bacterium. Gut Pathog. 2022; 14(1):1-20.
  25. Chen H, Chen Z, Wu B, Ullah J, Zhang T, Jia J, et al. Influences of various peptide linkers on the Thermotoga maritima MSB8 nitrilase displayed on the spore surface of Bacillus subtilis. Microb Physiol. 2017; 27(1):64-71.
  26. Ayyagari VS, TC V, Srirama K. Design of a multi-epitope-based vaccine targeting M-protein of SARS-CoV2: an immunoinformatics approach. J Biomol Struct Dyn. 2022; 40(7):2963-77.
  27. Yang Y, Sun W, Guo J, Zhao G, Sun S, Yu H, et al. In silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations. Hum Vaccin Immunother. 2015; 11(3):795-805.
  28. Bhatnager R, Bhasin M, Arora J, Dang AS. Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach. J Biomol Struct Dyn. 2021; 39(15):5690-705.
  29. Singh H, Jakhar R, Sehrawat N. Designing spike protein (S-Protein) based multi-epitope peptide vaccine against SARS COVID-19 by immunoinformatics. Heliyon. 2020; 6(11):e05528.
  30. Livingston B, Crimi C, Newman M, Higashimoto Y, Appella E, Sidney J, et al. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol. 2002; 168(11):5499-506.